Background: β-blocker use has been associated with improved outcomes in a number of different malignancies; however, the impact of β-blockade in esophageal cancer is not been well characterized. We compared the outcomes of esophageal cancer patients based on β-blocker usage. Methods: The charts of all 418 patients treated with radiation for esophageal cancer at our institution from April 2010 to October 2018 were analyzed. Patients who underwent treatment with palliative intent or did...
Fri Oct 09, 2020 03:00
Historically, the brain has been viewed as a specialized neurovascular inert organ with a distinctive immune privilege. Therefore, radiation-induced extracranial abscopal effects would be considered an unusual phenomenon due to the difficulty of the immunogenic signaling molecules to travel across the blood-brain barrier (BBB). However, it is now possible that localized central nervous system radiation has the ability to disrupt the structural integrity of the BBB and increase its endothelial permeability...
Fri Oct 09, 2020 03:00
British Journal of Cancer, Published online: 11 October 2020; doi:10.1038/s41416-020-01101-2Alcohol consumption, drinking patterns and cancer incidence in an Australian cohort of 226,162 participants aged 45 years and over
Sun Oct 11, 2020 03:00
Background Population‐based studies demonstrate that Black men in the United States have an increased risk of death from prostate cancer. Determinants of racial disparities are multifactorial, including socioeconomic and biologic factors. Methods The authors conducted a pooled analysis of patients derived from 152 centers within the Veterans Health Administration. The cohort included men who had nonmetastatic prostate diagnosed between 2001 and 2015 and received definitive radiation therapy....
Fri Oct 09, 2020 12:26
Background Disagreements between patients and caregivers about treatment benefits, care decisions, and patients' health are associated with increased patient depression as well as increased caregiver anxiety, distress, depression, and burden. Understanding the factors associated with disagreement may inform interventions to improve the aforementioned outcomes. Methods For this analysis, baseline data were obtained from a cluster‐randomized geriatric assessment trial that recruited patients...
Fri Oct 09, 2020 12:25
Background Clear cell papillary renal cell carcinoma (CCPRCC) shares histomorphologic and immunophenotypic features with clear cell RCC (CCRCC) and papillary RCC (PRCC). Methods We compared the cytomorphology, immunoprofile, and clinical management of CCPRCC (n = 18), CCRCC (n = 20), and PRCC (n = 18). Results Useful cytomorphologic features for comparing CCPRCC with CCRCC include 3‐dimensional clusters (72% vs 0%), papillae (50% vs 0%) and sheets (22% vs 70%), vasculature (papillary...
Fri Oct 09, 2020 12:36
Background The Paris System (TPS) for Reporting Urinary Cytology aims to standardize urine cytology reporting. Per TPS, the diagnosis of “suspicious for high‐grade urothelial carcinoma (SHGUC)” is applied in cases that have few urothelial cells with severe atypia but are quantitatively insufficient for a diagnosis of “high‐grade urothelial carcinoma (HGUC).” In our study, we compared the diagnostic accuracy and risk of malignancy (ROM) of these 2 categories to assess whether they could be combined...
Fri Oct 09, 2020 12:28
Abstract High-dose IL-2 induces cancer regression but its therapeutic use is limited due to high toxicities resulting from its broad cell targeting. In one strategy to overcome this limitation, IL-2 has been modified to selectively target the intermediate affinity IL-2R that broadly activates memory-phenotypic CD8+ T and NK cells, while minimizing Treg-associated tolerance. In this study, we modeled an alternative strategy to amplify tumor antigen-specific TCR transgenic CD8+...
Sat Oct 10, 2020 03:00
Abstract Cervical cancer remains among the most common cancers in women worldwide and can be prevented by vaccination. The Ministry of Health, Labour and Welfare of Japan suspended the active recommendation of regular HPV vaccines in 2013 due to various symptoms including chronic pain and motor impairment. This nationwide case‐control study from April 2013 to March 2017 targeted women aged 20–24 years old at cervical screening. We compared HPV vaccination exposure between those with abnormal and...
Sat Oct 10, 2020 21:33
Abstract DNA‐sensing receptor Cyclic GMP–AMP Synthase (cGAS) and its downstream signaling effector STimulator of INterferon Genes (STING) have gained significant interest in the field of tumor immunology, as a dysfunctional cGAS‐STING pathway associates with poor prognosis and worse response to immunotherapy. However, studies so far have not taken into account the polymorphic nature of the STING‐encoding STING1 gene. We hypothesized that the presence of allelic variance in STING1 would cause variation...
Sat Oct 10, 2020 21:29
Abstract Cyclin‐dependent kinase 12 (CDK12), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to ERBB2. In this report, CDK12 and ERBB2 co‐amplification was detected by targeted next‐generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and HER2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 co‐amplification with ERBB2 may be associated with tumor...
Sat Oct 10, 2020 17:48
Abstract Monomer tubulin polymerize into microtubules, which are highly dynamic and play a critical role in mitosis. Therefore, microtubule dynamics are an important target for anti‐cancer drugs. The inhibition of tubulin polymerization or de‐polymerization was previously targeted and exhibited efficacy against solid tumors. The novel small molecule PTC596 directly binds tubulin, inhibits microtubule polymerization, down‐regulates MCL‐1, and induces p53‐independent apoptosis in acute myeloid leukemia...
Fri Oct 09, 2020 18:41
Abstract Spartalizumab is a humanized IgG4/κ monoclonal antibody directed against human PD‐1. In this phase I study we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanced malignancies. Patients (n=18) with a range of tumor types received spartalizumab intravenously at doses of 1, 3, and 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or discontinuation at the discretion of the investigator or patient....
Thu Oct 08, 2020 20:44
Publication date: Available online 9 October 2020Source: Cancer/RadiothérapieAuthor(s): R. Msika, N. Tkatchenko, M. Robilliard, A. Fourquet, Y. Kirova
Sat Oct 10, 2020 16:32
Edoxaban is used for venous thromboembolism (VTE) treatment. Real‐life data are lacking about its use in long‐term therapy. We aimed to assess the efficacy and the safety of edoxaban for long‐term VTE treatment in a real‐life setting. Patients with VTE included in the Registro Informatizado Enfermedad TromboEmbólica (RIETE) registry, receiving edoxaban 60 or 30 mg daily were prospectively followed up to validate the benefit of using different dosages. The main outcome was the composite of VTE recurrences...
Sat Oct 10, 2020 21:21
Ex vivo (EV)‐derived megakaryocytes (MKs) have shown great promise as a substitute for platelets in transfusion medicine to alleviate a severe shortage of donor‐platelets. Challenges remain that include poor efficiency, a limited scale of production, and undefined short‐term storage conditions of EV‐derived MKs. This study aims to develop a high‐efficiency system for large‐scale production of Good Manufacturing Practice (GMP)‐grade MKs and determine the short‐term storage condition for the MKs. A...
Thu Oct 08, 2020 18:41
Purpose The role of immune-oncologic mechanisms of racial disparities in prostate cancer (PCa) remains understudied. Limited research exists to evaluate the molecular underpinnings of immune differences in African American (AAM) and European American (EAM) prostate tumor microenvironment (TME). Experimental Design A total of 1,173 radiation naïve radical prostatectomy samples with whole transcriptome data from the Decipher GRIDTM registry was used. Transcriptomic expressions of 1260 immune specific...
Fri Oct 09, 2020 16:24
In 2019, the FDA Oncology Center of Excellence (OCE) launched Project Orbis, a global collaborative review program to facilitate faster patient access to innovative cancer therapies across multiple countries. Project Orbis aims for concurrent submission, review, and regulatory action for high-impact clinically significant marketing applications among the participating partner countries. Current Project Orbis partners (POP) include the regulatory health authorities (RHA) of Australia, Brazil, Canada,...
Fri Oct 09, 2020 16:24
Purpose:Urothelial carcinoma is a malignant cancer with frequent chromosomal aberrations. Here, we investigated the application of a cost-effective, low-coverage whole-genome sequencing technology in detecting all chromosomal aberrations.Experimental Design:Patients with urothelial carcinomas and nontumor controls were prospectively recruited in clinical trial NCT03998371. Urine-exfoliated cell DNA was analyzed by Illumina HiSeq XTen, followed by genotyping with a customized bioinformatics workflow...
Fri Oct 09, 2020 10:05
Publication date: Available online 10 October 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Hélios Bertin, A. Gomez-Brouchet, F. Rédini
Sun Oct 11, 2020 14:58
Publication date: Available online 10 October 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Hatoon Bakhribah, Mohammad Zeitouni, Rayyan A. Daghistani, Hatim Q. Almaghraby, Azzam A. Khankan, Khaled M. Alkattan, Salem M Alshehri, Abdul Rahman Jazieh
Sat Oct 10, 2020 12:56
Opinion statement The mainstay treatment of localized non-melanoma skin cancer (NMSC) is surgical excision or Mohs surgery. However, approximately 5% of patients with NMSC harbor high-risk clinicopathologic features for loco-regional recurrence, and distant metastasis. Prognostic factors such as close or positive margins, tumor size ≥ 2 cm, poor tumor differentiation, perineural invasion, depth of invasion, and immunosuppression have all been associated with increased loco-regional...
Fri Oct 09, 2020 03:00
Publication date: November 2020Source: European Journal of Cancer, Volume 140Author(s): Daniel Orbach, Nicolas André, Ines B. Brecht, Ricardo López Almaraz, Tal Ben-Ami, Sophie Vermersch, Matthieu Carton, Calogero Virgone, Gianni Bisogno, Dominik T. Schneider, Viera Bajciova, Yves Reguerre, Françoise Galateau-Salle, Teresa Stachowicz-Stencel, Rina Dvir, Helen Rees, Ewa Bien, Andrea Ferrari, Myriam Ben Arush
Sun Oct 11, 2020 15:30
Publication date: Available online 9 October 2020Source: European Journal of CancerAuthor(s): Alba Rubio-San-Simón, Nicolas André, Maria Giuseppina Cefalo, Isabelle Aerts, Alicia Castañeda, Sarah Benezech, Guy Makin, Natasha van Eijkelenburg, Karsten Nysom, Lynley Marshall, Marion Gambart, Raquel Hladun, Claudia Rossig, Luca Bergamaschi, Franca Fagioli, Ben Carpenter, Stephane Ducassou, Cormac Owens, Ingrid Øra, Antonio Juan Ribelles
Sat Oct 10, 2020 15:07
Publication date: November 2020Source: European Journal of Cancer, Volume 140Author(s): Claudia Schweizer, Philipp Schubert, Sandra Rutzner, Markus Eckstein, Marlen Haderlein, Sebastian Lettmaier, Sabine Semrau, Antoniu-Oreste Gostian, Benjamin Frey, Udo S. Gaipl, Jian-Guo Zhou, Rainer Fietkau, Markus Hecht
Fri Oct 09, 2020 20:02
Publication date: November 2020Source: European Journal of Cancer, Volume 140Author(s): Frédéric Dumont, Christophe Passot, Jean-Luc Raoul, Vahan Kepenekian, Bénédicte Lelièvre, Michelle Boisdron-Celle, Sandrine Hiret, Hélène Senellart, Francois Pein, Audrey Blanc-Lapierre, Judith Raimbourg, Emilie Thibaudeau, Olivier Glehen, BIG-RENAPE Networks
Fri Oct 09, 2020 20:02
Publication date: November 2020Source: European Journal of Cancer, Volume 140Author(s): Young-Sun Lee, Young K. Jung, Ji H. Kim, Sung B. Cho, Do Y. Kim, Moon Y. Kim, Hyung J. Kim, Yeon S. Seo, Ki T. Yoon, Young M. Hong, Jeong-Hoon Lee, Hyun W. Lee, Hyung J. Yim, Byoung K. Jang, Eun S. Jang, Jae Y. Jang, Sang Y. Hwang
Fri Oct 09, 2020 20:02
Publication date: November 2020Source: European Journal of Cancer, Volume 140Author(s): Ying-Hsuan Tai, Hsiang-Ling Wu, Mercedes Susan Mandell, Shih-Pin Lin, Mei-Yung Tsou, Kuang-Yi Chang
Fri Oct 09, 2020 20:02
Publication date: November 2020Source: European Journal of Cancer, Volume 140Author(s): Masayuki Shirasawa, Tatsuya Yoshida, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Shun-ichi Watanabe, Yuichiro Ohe, Noriko Motoi
Fri Oct 09, 2020 20:02
Publication date: Available online 8 October 2020Source: European Journal of CancerAuthor(s): Constantine Alifrangis, Anand Sharma, Shafi Chowdhury, Sarah Duncan, Marina Milic, Andrew Gogbashian, Samita Agarwal, Anju Sahdev, Peter Wilson, Stephen Harland, Sara Stoneham, Michelle Lockley, Gordon Rustin, Timothy Oliver, Daniel Berney, Jonathan Shamash
Fri Oct 09, 2020 20:02
Publication date: Available online 8 October 2020Source: European Journal of CancerAuthor(s): Astrid Lièvre, Anthony Turpin, Isabelle Ray-Coquard, Karine Le Malicot, Juliette Thariat, Guido Ahle, Cindy Neuzillet, Xavier Paoletti, Olivier Bouché, Kais Aldabbagh, Pierre Michel, Didier Debieuvre, Anthony Canellas, Marie Wislez, Lucie Laurent, May Mabro, Raphael Colle, Anne-Claire Hardy-Bessard, Laura Mansi, Emeline Colomba
Fri Oct 09, 2020 20:02
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): L. De Rooij, J.W.A.M. Bosmans, S.M.J. van Kuijk, Y.L.J. Vissers, G.L. Beets, J. van Bastelaar
Sun Oct 11, 2020 16:57
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Otsuka
Sun Oct 11, 2020 16:57
Publication date: Available online 8 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tian-Ming Gao, Dou-Sheng Bai, Jian-Jun Qian, Chi Zhang, Sheng-Jie Jin, Guo-Qing Jiang
Fri Oct 09, 2020 15:22
Future Oncology, Ahead of Print.
Fri Oct 09, 2020 13:51
Future Oncology, Ahead of Print.
Thu Oct 08, 2020 11:20
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncol. 2020 Oct 09;: Authors: Merz V, Zecchetto C, Melisi D Abstract The prognosis of patients affected by cholangiocarcinoma is classically poor. Until recently, chemotherapeutic drugs were the only systemic treatment option available, leading to an overall survival lower than 1 year. In recent decades, different genetic alterations have been identified...
Sat Oct 10, 2020 13:17
Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. Future Oncol. 2020 Oct 08;: Authors: Patel A, Ravaud A, Motzer RJ, Pantuck AJ, Staehler M, Escudier B, Martini JF, Lechuga M, Lin X, George DJ Abstract Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant...
Fri Oct 09, 2020 17:26
Abstract The diagnosis of epithelioid hemangioma (EH) remains challenging due to its rarity, worrisome histologic features, and locally aggressive clinical and radiographic presentation. Especially in the bone, EH can be misdiagnosed as a malignant vascular neoplasm due its lytic, often destructive or multifocal growth, as well as atypical morphology. The discovery of recurrent FOS and FOSB gene fusions in the pathogenesis of most EH has strengthened its stand‐alone classification, distinct from...
Fri Oct 09, 2020 16:25
Abstract Obesity is a risk factor for several major cancers. Associations of weight change in middle adulthood with cancer risk, however, are less clear. We examined the association of change in weight and body mass index (BMI) category during middle adulthood with 42 cancers, using multivariable Cox proportional hazards models in the European Prospective Investigation into Cancer and Nutrition cohort. Of 241 323 participants (31% men), 20% lost and 32% gained weight (>0.4 to 5.0 kg/year) during...
Sat Oct 10, 2020 22:40
Abstract Myeloproliferative neoplasms (MPNs) are a group of diseases that cause myeloid hematopoietic cells to over‐proliferate. Epidemiological and familial studies suggest that genetic factors contribute to the risk of developing MPN, but the genetic susceptibility of MPN is still not well known. Indeed, only few loci are known to have a clear role in the predisposition to this disease. Some studies reported a diagnosis of MPNs and multiple myeloma (MM) in the same patients, but the biological...
Sat Oct 10, 2020 22:40
Abstract Prostate cancer (PCa) progression is driven by androgen receptor (AR) signaling. Unfortunately, androgen‐deprivation therapy and the use of even more potent AR pathway inhibitors (ARPIs) cannot bring about a cure. ARPI resistance (i.e. castration‐resistant PCa, CRPC) will inevitably develop. Previously, we demonstrated that GRB10 is an AR transcriptionally‐repressed gene that functionally contributes to CRPC development and ARPI resistance. GRB10 expression is elevated prior to CRPC development...
Sat Oct 10, 2020 22:40
Abstract The liver ischemia‐reperfusion (IR) injury that occurs consequently to hepatic resection performed in patients with metastases can lead to tumor relapse for not fully understood reasons. We assessed the effects of liver IR on tumor growth and the innate immune response in a mouse model of colorectal liver metastasis (CRLM). Mice subjected to liver ischemia two days after intrasplenic injection of colorectal carcinoma cells displayed a higher metastatic load in the liver, correlating with...
Sat Oct 10, 2020 22:36
Abstract Few data exists on health‐related quality of life (QoL) in patients with metastatic pancreatic cancer receiving first‐line chemotherapy 1. The QOLIXANE study is a prospective, non‐interventional, multicenter sub‐study of the Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with metastatic pancreatic cancer receiving first‐line gemcitabine and nab‐paclitaxel chemotherapy in real‐life setting. QoL was...
Sat Oct 10, 2020 22:36
Abstract Obesity is considered a chronic inflammatory state characterised by continued secretion of adipokines and cytokines. Experimental and epidemiological evidence indicates that circulating adipokines may be associated with the development of obesity‐related cancers, but it is unclear if these associations are causal or confounded. We examined potential causal associations of specific adipokines [adiponectin, leptin, soluble leptin receptor (sOB‐R), and plasminogen activator inhibitor‐1 (PAI‐1)]...
Sat Oct 10, 2020 22:33
Abstract Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine (T4) and its active form 3,5,3'‐triiodo‐L‐thyronine (T3) are involved in the progression of PCa. Epidemiologic evidences show a higher incidence of PCa in men with elevated thyroid hormone levels. The thyroid hormone binding protein μ‐Crystallin (CRYM) mediates...
Fri Oct 09, 2020 22:24
Abstract To compare the efficacy and safety of radiotherapy (RT) and chemotherapy of pegaspargase, gemcitabine, cisplatin and dexamethasone (DDGP) combined with RT in newly diagnosed stage I‐II natural killer/T‐cell lymphoma (NKTL), we designed a randomized, controlled, open‐label, multicenter clinical trial. Data from 65 I‐II NKTL patients whose diagnoses were confirmed using immunohistochemistry were enrolled from January 2011 to December 2013 in the First Affiliated Hospital of Zhengzhou University....
Fri Oct 09, 2020 22:20
Abstract Most women with ovarian cancer have a poor prognosis, but studies have reported an association between statin use and improved survival. We investigated the potential survival benefit of statins in women with ovarian cancer using data from the Ovarian cancer Prognosis and Lifestyle (OPAL) study, a prospective study of Australian women aged 18‐79, diagnosed with ovarian cancer from 2012‐2015 and followed for 5‐8 years. We obtained information from patient‐completed questionnaires and medical...
Fri Oct 09, 2020 22:20
Abstract Clear cell carcinomas of the gynecologic tract are aggressive tumors with high resistance rate to conventional platinum‐based chemotherapies. Currently, the molecular features of these tumors remain largely unknown and there is no targeted therapy available. The aim of our study was to identify anaplastic lymphoma kinase (ALK) translocations, a potential molecular target for therapy. Ninety‐seven patients with gynecologic clear cell carcinoma (62 ovarian, 27 uterine corpus, and 8 uterine...
Fri Oct 09, 2020 22:19
Abstract Angiogenesis is a prerequisite for multiple myeloma development. Tumor cells can stimulate angiogenesis by secreting vascular endothelial growth factor A (VEGFA), but we previously reported that tumor angiogenesis was not significantly reduced when VEGFA expression was inhibited in myeloma cells. Tumor-associated macrophages (TAMs) are important components of the tumor microenvironment and have been reported to be involved in the regulation of angiogenesis. In this...
Sat Oct 10, 2020 03:00
Abstract Prostate-specific membrane antigen (PSMA; also termed glutamate carboxypeptidase II (GCP II)) is abundantly expressed in prostate cancer. It has been shown recently that PSMA is expressed in neovasculature of differentiated thyroid cancer. In this study, we show that 18F-DCFPyl might detect neovasculature in advanced, metastatic differentiated thyroid cancer (DTC). We first stained the preserved lymph node samples of three patients with DTC who had undergone total thyroidectomy...
Fri Oct 09, 2020 03:00
Targeting dormant ovarian cancer cells in vitro and in an in vivo mouse model of platinum resistance
Spheroids exhibit drug resistance and slow proliferation, suggesting involvement in cancer recurrence. The protein kinase C inhibitor, UCN-01 (7-hydroxystaurosporine) has shown higher efficacy against slow proliferating and/or quiescent ovarian cancer cells. In this study, tumorigenic potential was assessed using anchorage independent growth assays and spheroid forming capacity, which was determined with ovarian cancer cell lines as well as primary ovarian cancers. Of 12 cell lines with increased...
Fri Oct 09, 2020 18:24
Activation of TRAILR2 has emerged as an important therapeutic concept in cancer treatment. TRAILR2 agonistic molecules have only had limited clinical success, to date, due either to lack of efficacy or hepatotoxicity. BI 905711 is a novel tetravalent bispecific antibody targeting both TRAILR2 and CDH17 and represents a novel liver-sparing TRAILR2 agonist specifically designed to overcome the disadvantages of previous strategies. Here, we show that BI 905711 effectively triggered apoptosis in a broad...
Fri Oct 09, 2020 18:24
The PI3K/AKT/mTOR pathway is often activated in lymphoma through alterations in PI3K, PTEN and B-cell receptor signaling, leading to dysregulation of eIF4A (through its regulators, eIF4B, eIF4G and PDCD4) and the eIF4F complex. Activation of eIF4F has a direct role in tumorigenesis due to increased synthesis of oncogenes that are dependent on enhanced eIF4A RNA helicase activity for translation. eFT226, which inhibits translation of specific mRNAs by promoting eIF4A1 binding to 5'-untranslated regions...
Fri Oct 09, 2020 18:24
Pancreatic ductal adenocarcinoma (PDAC) has a prominent fibrotic stroma, which is a result of interactions between tumor, immune and pancreatic stellate cells (PSC) or cancer associated fibroblasts (CAF). Targeting inflammatory pathways present within the stroma may improve access of effector immune cells to PDAC and response to immunotherapy. Heat shock protein-90 (Hsp90), is a chaperone protein and a versatile target in pancreatic cancer. Hsp90 regulates a diverse array of cellular processes of...
Fri Oct 09, 2020 18:24
Goblet cell carcinoid (GCC) is a distinct subtype of appendiceal neoplasm that exhibits unique clinical and pathologic features. We aimed to reveal the molecular profiles of GCC compared to other appendiceal tumors, such as adenocarcinoma and neuroendocrine tumor (NET). A total of 495 appendiceal tumor samples (53 GCCs, 428 adenocarcinomas, and 14 NETs) were tested with next-generation sequencing (NGS) on a 592-gene panel and immunohistochemistry (IHC). Microsatellite instability (MSI)/mismatch repair...
Fri Oct 09, 2020 18:24
Abstract Purpose This study was performed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of the immunomodulatory agent, lenalidomide, when administered daily during 6 weeks of radiation therapy to children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) Patients & methods ...
Sun Oct 11, 2020 03:00
Abstract Purposes Immunotherapies for solid tumor are gaining traction in the clinic, however, the immunological landscape of pituitary adenomas (PAs) is not well defined. In the present study, we used the RNA-seq data of PAs to investigate the impact of immunological landscape on clinical features of pituitary adenomas and aim to evaluate the potential immunotherapy for PAs. ...
Fri Oct 09, 2020 03:00
Abstract Purpose The purpose of this study is to describe the long-term toxicities of intracranial germ cell tumor (IGCT) in the adolescent and young adult (AYA) population. Methods We report late toxicities of a multi-center cohort of AYA patients treated for IGCT between 1975 and 2015. Charts were retrospectively reviewed for hormone deficiency,...
Fri Oct 09, 2020 03:00
Abstract Purpose Cyclin-dependent kinase-retinoblastoma (CDK-RB) pathway is dysregulated in some diffuse intrinsic pontine gliomas (DIPG). We evaluated safety, feasibility, and early efficacy of the CDK4/6-inhibitor ribociclib, administered following radiotherapy in newly-diagnosed DIPG patients. Methods Following radiotherapy, eligible patients received...
Fri Oct 09, 2020 03:00
Publication date: Available online 9 October 2020Source: Practical Radiation OncologyAuthor(s): Roberta Castriconi, Giovanni Mauro Cattaneo, Paola Mangili, Piergiorgio Esposito, Sara Broggi, Cesare Cozzarini, Chiara Deantoni, Andrei Fodor, Nadia G. Di Muzio, Antonella del Vecchio, Claudio Fiorino
Fri Oct 09, 2020 17:07
Abstract Objective Early access to work‐related psychosocial cancer care can contribute to return to work of cancer survivors. We aimed to explore: 1) the extent to which hospital health care professionals conduct conversations about work‐related issues with cancer survivors, 2) whether cancer survivors experience these conversations as helpful, and 3) the possible financial implications for cancer survivors of (not) discussing their work early on. Methods The Dutch Federation of Cancer...
Sat Oct 10, 2020 15:16
Abstract OBJECTIVEEnd‐of‐life (EOL) care is a developing concept in India, with well‐established practices in certain states like Kerala, but not in all the states. As there is a substantial stigma associated with death discussion across the Indian population, the experiences of caregivers of people with advanced cancer have not been explored. Our aim in this study was to explore the experience and perceptions of caregivers of people diagnosed with advanced cancer regarding the quality of the individuals’...
Sat Oct 10, 2020 15:16
Abstract Background People living with advanced cancer experience significant distress and reduced quality of life due to their symptom burden and life‐limiting prognosis. Limited qualitative research has investigated their experiences accessing psychosocial supportive care, and how it meets their needs. Aim To explore patients’ perspectives of the role of psychosocial support in their experiences of living with advanced cancer. Methods This study used an exploratory qualitative research...
Sat Oct 10, 2020 10:29
To evaluate the clinical outcomes of combination of androgen deprivation therapy (ADT), whole pelvic radiotherapy (WPRT), and stereotactic body radiotherapy (SBRT) boost in high-risk prostate cancer patients.
Thu Oct 08, 2020 03:00
The impact of the COVID-19 pandemic on cancer death was reported recently[1].Wuhan where COVID-19 broke out has been critically hit[2–3]. The emergence has affected every aspect of health care, including the delivery of standard radiotherapy to patients with cancer. Those patients was facing disruption because of concerns about their susceptibility to the serious risks of COVID-19, travel restrictions, and the shortage of personnel, beds and personal protective equipment, and it has been reported...
Sun Oct 11, 2020 03:00
Publication date: December 2020Source: Cancer Epidemiology, Volume 69Author(s): Heikki Seikkula, Elli Hirvonen, Antti Kaipia, Peter J. Boström, Nea Malila, Janne Pitkäniemi
Sat Oct 10, 2020 19:35
Publication date: December 2020Source: Cancer Epidemiology, Volume 69Author(s): Chun-Pin Chang, Travis J. Meyers, Alan Fu, Ming-Yan Zhang, Donald P. Tashkin, Jian-Yu Rao, Wendy Cozen, Thomas M. Mack, Mia Hashibe, Hal Morgenstern, Zuo-Feng Zhang
Fri Oct 09, 2020 18:32
Publication date: December 2020Source: Cancer Epidemiology, Volume 69Author(s): Rita Peila, Rhonda S. Arthur, Thomas E. Rohan
Fri Oct 09, 2020 18:32
Publication date: December 2020Source: Cancer Epidemiology, Volume 69Author(s): Laia Palència, Josep Ferrando, Marc Marí-Dell’Olmo, Mercè Gotsens, Joana Morrison, Dagmar Dzurova, Michala Lustigova, Claudia Costa, Maica Rodríguez-Sanz, Lucia Bosakova, Paula Santana, Carme Borrell
Fri Oct 09, 2020 18:32
Abstract Purpose To develop a videofluoroscopy-based predictive model of radiation-induced dysphagia (RID) by incorporating DVH parameters of swallowing organs at risk (SWOARs) in a machine learning analysis. Methods Videofluoroscopy (VF) was performed to assess the penetration-aspiration score (P/A) at baseline and at 6 and 12 months after RT. An...
Fri Oct 09, 2020 03:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου